8-K: TriSalus Life Sciences Reports Strong Q1 2024 Revenue Growth and Secures Debt Financing

TriSalus Life Sciences announced a 116% increase in revenue for Q1 2024 compared to Q1 2023, along with securing up to $50 million in debt financing.

Summary

• TriSalus Life Sciences reported a significant 116% increase in revenue for the first quarter of 2024, reaching $6.5 million, compared to $2.984 million in the same period last year.
• The company's gross margin also improved to 85% in Q1 2024, up from 78% in Q1 2023, due to increased factory volumes and improved operational efficiency.
• TriSalus secured up to $50 million in debt financing with OrbiMed, with an initial $25 million borrowed at closing and an additional $25 million available in two tranches upon achieving certain revenue targets.
• The company expects the initial $25 million draw, along with $4 million in cash on hand, to fund operations through the end of 2024.
• Including existing liquidity sources and assuming the remaining $25 million is borrowed, TriSalus anticipates sufficient cash to fund operations through the end of 2025.
• Operating losses for Q1 2024 were $11.7 million, compared to $10.1 million in Q1 2023, due to increased investments in sales, marketing, research and development, and general and administrative costs.
• Net losses available to common stockholders were $13.2 million in Q1 2024, compared to $8.3 million in Q1 2023, impacted by non-cash related gains and losses.
• Basic and diluted loss per share for Q1 2024 was $0.60, compared to $0.57 in Q1 2023.

Sentiment

Score: 8

Explanation: The document shows strong positive momentum with significant revenue growth and secured financing, although losses are increasing. The overall outlook is positive, but the company needs to manage its expenses and achieve revenue targets to access the full debt facility.

Positives

• The company experienced a substantial 116% increase in revenue year-over-year for Q1 2024.
• Gross margins improved significantly to 85% in Q1 2024.
• The $50 million debt financing provides a strong financial foundation for growth initiatives.
• The appointment of Liselotte Hyveled to the board brings valuable experience.
• The company expects full year sales growth to exceed 50%.

Negatives

• Operating losses increased to $11.7 million in Q1 2024 from $10.1 million in Q1 2023.
• Net losses available to common stockholders increased to $13.2 million in Q1 2024 from $8.3 million in Q1 2023.
• Basic and diluted loss per share increased to $0.60 in Q1 2024 from $0.57 in Q1 2023.

Risks

• The company's ability to access the additional $25 million in debt financing is contingent on achieving certain revenue thresholds.
• The company's future clinical results may not be consistent with patient data generated during the company's clinical trials.
• The company may need to raise additional capital through the issuance and sale of its equity securities to fund its operations.
• The company faces risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates.
• The company faces risks associated with the credit facility, including the company's ability to remain in compliance with all its obligations thereunder to avoid an event of default.

Future Outlook

The company expects full year sales growth to exceed 50% and anticipates sufficient cash to fund operations through the end of 2025, assuming they achieve revenue targets and borrow the remaining $25 million of the debt financing.

Management Comments

• Mary Szela, Chief Executive Officer of TriSalus, stated she is proud to highlight the strong start in the first quarter of 2024 with 116% growth in revenues.
• Mary Szela also stated that the company is confident in its ability to execute its company-building strategy due to recent positive developments in reimbursement, clinical data, and the dedication of the executive team.
• Management stated that their objectives of achieving over 50% top-line revenue growth, advancing their pipeline, and strengthening their operational foundations remain firmly on track.

Industry Context

This announcement highlights TriSalus's progress in the oncology space, particularly with its novel drug delivery technology. The company's focus on liver and pancreatic tumors aligns with the growing need for innovative treatments in these areas. The secured debt financing positions them to further develop their technology and expand their market presence.

Comparison to Industry Standards

• The 116% revenue growth in Q1 2024 is significantly higher than the average growth rate for many medical device and biotech companies, suggesting strong market adoption of their TriNav Infusion System.
• The 85% gross margin is also very high, indicating efficient operations and strong pricing power, which is favorable compared to many companies in the medical device sector.
• While the company is experiencing increased losses, this is not uncommon for growth-stage biotech companies that are investing heavily in R&D and commercialization. Companies like Exact Sciences and Incyte have also experienced significant losses during their growth phases.
• The debt financing secured with OrbiMed is a common strategy for biotech companies to fund growth, similar to companies like BioMarin and Alnylam, which have also used debt financing to support their operations and development programs.

Management Changes

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and secured financing positively.
• Employees may benefit from the company's growth and expansion.
• Customers (healthcare providers) will have access to innovative treatment options.
• Suppliers may see increased demand for their products and services.
• Creditors will be interested in the company's ability to meet its debt obligations.

Next Steps

• The company will continue to focus on achieving over 50% top-line revenue growth.
• The company will advance its pipeline.
• The company will strengthen its operational foundations.
• The company will continue to develop and commercialize its TriNav Infusion System.
• The company will continue to study nelitolimod across several indications.

Key Dates

Keywords

TriSalus, revenue growth, debt financing, gross margin, TriNav Infusion System, OrbiMed, financial results, oncology, drug delivery, nelitolimod